Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596867 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Propanolol in Breast Cancer
A Phase 2 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02596867 is a Phase 2 study that was terminated before completion, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 2 participants.
The verdict
NCT02596867, a Phase 2 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center, El Paso.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This trial is a Phase II study using the "window-of-opportunity" design in which the treatment-free window between breast cancer diagnosis and surgical tumor resection is used to study the biological effects of the beta blocker propranolol .
Interventions
- DRUG propanolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02596867
The ClinicalTrials.gov registry entry for NCT02596867 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which propanolol is the first listed.
NCT02596867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02596867 about?
NCT02596867 is a clinical study titled "Neoadjuvant Propanolol in Breast Cancer". This trial is a Phase II study using the "window-of-opportunity" design in which the treatment-free window between breast cancer diagnosis and surgical tumor resection is used to study the biological effects of the beta blocker propranolol .
What is the current status of trial NCT02596867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-09-01. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT02596867?
The interventions under investigation include: propanolol (DRUG).
Who is sponsoring clinical trial NCT02596867?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.